Related Experiment Videos
In-vitro glucocorticoid studies for predicting response to glucocorticoid therapy in adults with malignant lymphoma
Abstract:
Neoplastic tissues from 28 adults with malignant lymphoma were examined for glucocorticoid receptors and in-vitro sensitivity to glucocorticoids. The patients were then treated with desamethasone for 5--14 days. 13 patients achieved at least a partial remission, and 15 had no significant tumour response. Lymphoma cells from patients who responded had more glucocorticoid-receptor sites per cell and greater in-vitro sensitivity as measured by glucocorticoid inhibition of incorporation of leucine and uridine than did tumour cells from non-responders. Study of tumour glucocorticoid receptors and glucocorticoid sensitivity in vitro may allow selection of those patients with lymphoma who should receive glucocorticoids as part of combination chemotherapy.
Insights
Glucocorticoid receptors in malignant lymphoma predict treatment response. Patients with more receptors and higher sensitivity showed better outcomes with dexamethasone, suggesting a method for selecting patients for glucocorticoid therapy.
Area of Science:
- Oncology
- Pharmacology
Background:
- Malignant lymphoma is a significant hematologic malignancy.
- Glucocorticoids are used in lymphoma treatment, but patient response varies.
- Predictive biomarkers for glucocorticoid therapy are needed.
Purpose of the Study:
- To investigate the correlation between glucocorticoid receptor (GR) levels and in-vitro sensitivity in lymphoma cells.
- To determine if GR status can predict patient response to dexamethasone treatment.
- To evaluate the potential of using GR and sensitivity assays for patient selection in combination chemotherapy.
Main Methods:
- Analysis of neoplastic tissues from 28 adult patients with malignant lymphoma.
- Quantification of glucocorticoid receptors and assessment of in-vitro sensitivity to glucocorticoids.
- Clinical evaluation of patient response to 5-14 days of dexamethasone treatment.
Main Results:
- Patients achieving partial remission had significantly higher GR sites per cell compared to non-responders.
- Lymphoma cells from responders exhibited greater in-vitro sensitivity to glucocorticoids.
- In-vitro sensitivity was measured by glucocorticoid inhibition of leucine and uridine incorporation.
Conclusions:
- Tumor glucocorticoid receptor levels and in-vitro sensitivity are potential predictive markers for dexamethasone efficacy in malignant lymphoma.
- These assays may aid in selecting lymphoma patients who will benefit from glucocorticoid-containing chemotherapy regimens.
- Further research can refine the use of these biomarkers for personalized treatment strategies.